Who are Glatiramer acetate (GA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): histamine dihydrochloride and IL-2, Total Glucosides Paeony Capsules, Interferon-Alpha, Peg-IFN + WB RBV for 24 weeks, Thymosin Alpha, intralesional vitamin D3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glatiramer-acetate-ga.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glatiramer acetate (GA) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glatiramer acetate (GA) (Glatiramer acetate (GA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; disease-modifying therapy (DMT). Area: Immunology; Neurology.

marketed Immunomodulator; disease-modifying therapy (DMT) Immunology; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Glatiramer acetate (GA) (Glatiramer acetate (GA)) — Teva Branded Pharmaceutical Products R&D, Inc.. Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting the differentiation of T cells toward anti-inflammatory phenotypes and reducing autoreactive T cell responses in multiple sclerosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glatiramer acetate (GA) TARGET	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Total Glucosides Paeony Capsules	Total Glucosides Paeony Capsules	Sun Yat-sen University	marketed	Herbal extract immunomodulator
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Thymosin Alpha	Thymosin Alpha	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Immunomodulator
intralesional vitamin D3	intralesional vitamin D3	Combined Military Hospital Abbottabad	marketed	Vitamin D analog / immunomodulator	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; disease-modifying therapy (DMT) class)

Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
Federal University of São Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glatiramer acetate (GA) — Competitive Intelligence Brief. https://druglandscape.com/ci/glatiramer-acetate-ga. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab